UNSPSC 51263152: Bisoprolol hemifumarate

This classification denotes a beta-adrenergic blocking agent with the molecular formula 2C18H31NO4.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UR59KN573L, chemically known as 2-propanol, 1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)amino)-, (+/-)-, (e)-2-butenedioate (2:1) (salt), but more generally known as bisoprolol hemifumarate, which bears US NIH Compound Identifier 2405.

European Medicines Agency schedules bisoprolol hemifumarate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13096MIG. Most nations, for tariff purposes, schedule bisoprolol hemifumarate under HS 29221980. SMILES: CC(C)NCC(COC1CCC(CC1)COCCOC(C)C)O.CC(C)NCC(COC1CCC(CC1)COCCOC(C)C)O.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51263152 Bisoprolol hemifumarate is a Commodity code for a specific beta-blocker medication, but the recent state and local opportunities posted under this code show a mismatch between the nominal scope and actual procurement activity. The code shows little relevant recent activity aligned with bisoprolol procurement; instead, the tagged opportunities involve naloxone procurement and pharmacy benefit program design — neither of which relates directly to bisoprolol supply or fulfillment.

The geographic spread captured in the available records reflects Florida and Texas, with Seminole County, Florida posting an IFB on June 30, 2026 for Naloxone and Safe Drug Deactivation Systems (1,900 units of naloxone and 800 deactivation systems annually, with a response deadline of July 26, 2023), and the Texas Health and Human Services Commission issuing a Request for Information on April 3, 2026 regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Texas RFI seeks vendor capabilities for direct contracting between state pharmacy benefit programs and pharmaceutical manufacturers, but does not address bisoprolol or any specific pharmaceutical commodity. The code's alignment with actual state and local pharmaceutical procurement remains unclear given these discrepancies.